Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 9/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28563886 | 1.00 | USP30 (0.53) | USP30SCN9AKDM4EPKMGPR119 | |
| SCHEMBL2604335 | 0.93 | KDM4E (0.53) | USP30KDM4EPKMGPR119PARP1 | |
| SCHEMBL31184445 | 0.93 | KDM4E (0.53) | USP30KDM4EPKMGPR119PARP1 | |
| SCHEMBL22716791 | 0.91 | NAMPT (0.46) | USP30SCN9AKDM4EPKMGPR119 | |
| SCHEMBL28566888 | 0.85 | USP30 (0.55) | USP30SCN9APARP1ALDH1A1NPC1 | |
| SCHEMBL28566889 | 0.85 | USP30 (0.55) | USP30SCN9APARP1ALDH1A1NPC1 | |
| SCHEMBL23758477 | 0.85 | USP30 (0.48) | USP30SCN9AKDM4EPKMGPR119 | |
| SCHEMBL16269040 | 0.85 | SCN9A (0.51) | USP30SCN9AKDM4EPKMGPR119 | |
| SCHEMBL4141424 | 0.85 | USP30 (0.56) | USP30SCN9AKDM4EPKMGPR119 | |
| SCHEMBL5758822 | 0.85 | SCN9A (0.51) | USP30SCN9AKDM4EPKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| CN-108290861-B | 1-cyano-pyrrolidine derivatives as USP30 inhibitors | 特殊治疗有限公司 | 2021-05-25 | — | — | CN | disclosed |
| WO-2017093718-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30. | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | USP30, USP1, USP20 | USP30 1/4885SCN9A 3277/4885KDM4E 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.